Navigation Links
Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
Date:12/8/2008

cal and related costs of obesity are $123 billion per year according to a 2005 report by the International Diabetes Federation. Being obese or overweight is associated with increased risk of a number of conditions, including heart disease, stroke, diabetes, cancer and osteoarthritis. Medical treatment options for obese and overweight people currently are limited.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic indication, tolerability, side effects, efficacy and potential of lorcaserin; future results of clinical trials; future activities and announcements relating to lorcaserin, including the BLOOM results and the submission of an NDA for lorcaserin; and about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ mater
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
2. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
3. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
4. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
5. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
6. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
8. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
11. Arena Pharmaceuticals Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Albuquerque, New Mexico (PRWEB) May 21, 2013 ... Practical Perspective for Caregivers ” has over 50 years ... years was the process of losing both her mom ... years has been serving as a volunteer with the ... experiences have given her an understanding and insight into ...
(Date:5/21/2013)... Canadian-based FundRazr has 25 million reasons why ... has accumulated a list of our 25 Most Notable ... this week. Among them is the DC Entertainment and ... from video gamers, on-going legal fees support for the ... Tiger Woods sending underserved kids to school, lifesaving health ...
(Date:5/21/2013)... HealthDay Reporter , , MONDAY, May 20 (HealthDay News) -- ... critically ill patients who have been placed on ventilators, ... according to a new study. Intensive care unit ... choice whenever they liked enjoyed a 36 percent reduction ... music, researchers found. The ICU patients who were ...
(Date:5/21/2013)... Amy Norton HealthDay Reporter , , MONDAY, May 20 ... has become the norm for prostate cancer in the United ... -- at least for some men, a new study suggests. ... who had radiation therapy after prostate cancer surgery, the newer ... advantage over the conventional version. Men who received ...
(Date:5/21/2013)... May 21, 2013 Dr. James C. ... Director of the Sarcoma Division of the John Theurer ... Jersey has been named one of the top 13 ... Week. Dr. Wittig is one of approximately 125 ... list was created by surveying thought leaders in the ...
Breaking Medicine News(10 mins):Health News:International Book Release on Alzheimer’s Care-giving by Barbara Michels “The Alzheimer’s Journey…A Practical Perspective for Caregivers 2Health News:International Book Release on Alzheimer’s Care-giving by Barbara Michels “The Alzheimer’s Journey…A Practical Perspective for Caregivers 3Health News:International Book Release on Alzheimer’s Care-giving by Barbara Michels “The Alzheimer’s Journey…A Practical Perspective for Caregivers 4Health News:Favorite Music May Ease Anxiety in ICU Patients 2Health News:Favorite Music May Ease Anxiety in ICU Patients 3Health News:Newer, Pricier Prostate Cancer Radiation No Better Than Old: Study 2Health News:Newer, Pricier Prostate Cancer Radiation No Better Than Old: Study 3Health News:Newer, Pricier Prostate Cancer Radiation No Better Than Old: Study 4Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 2Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 3
... INDIANAPOLIS The perception of discrimination increases the amount ... amount teenage minority girls smoke, according to a new ... This study, to be published in the March 2010 ... , has been posted by the journal under "First ...
... levels of flame retardant compounds called polybrominated diphenyl ethers ... children, according to researchers at the Columbia Center for ... of Public Health. The study is ... be released in the April 2010 print issue. ...
... in test for cervical cancer, but U.S. experts are mixed ... the human papillomavirus should replace the Pap smear as the ... Italian researchers. , Their recommendation is based on a study ... cases of cervical cancer than the conventional Pap smear. Results ...
... , ... LeonardoMD has partnered with ... complement LeonardoMD’s premier web-based practice management software. The MedAppz ... which is primarily focused on streamlining the flow of patients ...
... ... announced that it will be supporting the rapidly-growing network of retailers carrying its ... to include direct response mailings, television commercials, national sponsorships, and additional print advertising. ... ...
... MINNEAPOLIS , Jan. 19 The National Theatre for ... agreement with the only global entertainment brand dedicated to kids health, ... and healthy exercise to the kids and families who need it ... NTC will tour a curriculum-based and interactive live show – performed ...
Cached Medicine News:Health News:Minority teen boys smoke more when they perceive discrimination; girls do not 2Health News:Prenatal exposure to flame-retardant compounds affects neurodevelopment of young children 2Health News:Should HPV Test Replace the Pap Smear? 2Health News:Should HPV Test Replace the Pap Smear? 3Health News:LeonardoMD Partners with MedAppz to Provide Web-Based CCHIT-Certified Electronic Health Record 2Health News:LeonardoMD Partners with MedAppz to Provide Web-Based CCHIT-Certified Electronic Health Record 3Health News:LeonardoMD Partners with MedAppz to Provide Web-Based CCHIT-Certified Electronic Health Record 4Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 2Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 3Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 4Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 5Health News:World's #1 Health Brand for Kids Joins Forces With World's #1 In-School Children's Theatre 2Health News:World's #1 Health Brand for Kids Joins Forces With World's #1 In-School Children's Theatre 3Health News:World's #1 Health Brand for Kids Joins Forces With World's #1 In-School Children's Theatre 4
(Date:5/20/2013)... Pa. , May 20, 2013  B. ... patient, clinician and environmental safety with products, services ... B.Braun will feature its innovative Outlook® 400ES and ... and barcoding capabilities at the American Association of ... at the Boston Convention ...
(Date:5/20/2013)... , May 20, 2013  Valeant Pharmaceuticals International, Inc. (NYSE: ... its senior management team will make a presentation at the ... June 11, 2013 at 9:20 a.m. PT. The conference will ... Angeles, CA. A live webcast and ... company,s Web site at www.valeant.com . Click on Investor ...
(Date:5/20/2013)... BATESVILLE, Ind. , May 20, 2013  Hill-Rom ... to listen to a management presentation at the 38 ... Boston on May 30, 2013, ... ) You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at ...
Breaking Medicine Technology:B. Braun Committed To Improving Patient Safety 2
... 2011 ARKRAY announced today that it has been ... the group purchasing unit of the Premier healthcare alliance, ... all Premier Continuum of Care members, at their discretion, ... by Premier for ARKRAY,s Blood Glucose Meters and Reagents, ...
... Inc. today announced that it has completed patient enrollment ... the MiStent® Drug-Eluting Coronary Stent System. The MiStent DES ... drug/polymer coating formulation. Enrollment of 183 patients across 26 ... ahead of schedule. Micell previously announced that, ...
Cached Medicine Technology:ARKRAY Awarded Blood Glucose Meters Agreement With the Premier Healthcare Alliance for Non-Acute Members 2Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent® Drug-Eluting Coronary Stent 2Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent® Drug-Eluting Coronary Stent 3
Micro dressing forceps....
... Leica M520 OH3 is a ... optical performance available on the ... unique stand. The Leica M520 ... the greatest range of movement ...
Advanced operating microscope with zoom and variable focus up to 500 mm....
DUALSWITCH-SHUNTSYSTEM for L-P-Derivation...
Medicine Products: